the Image

Clinical Trial Details

If you are a patient or a caregiver and would like to learn more our cancer clinical trials call toll-free 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials) or email cancerclinicaltrials@bsd.uchicago.edu .

Share this:
Brief Title Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.
Official Title Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib After Completion of Ibrutinib Clinical Trials.
Principal Investigator Smith, Sonali
Brief Summary Multicenter, open-label, prospective treatment protocol that provides continued access to ibrutinib to subjects who have completed parent ibrutinib studies, are still benefitting from treatment with ibrutinib, and have no access to commercial ibrutinib for their underlying disease within their region.
Gender All
Ages 18 Years
Enrollment 500
Accepts Healthy Volunteers No
Lead Sponsor Pharmacyclics Switzerland GmbHIndustry
Collaborator
Study Design
Study Phase Phase 4
Study Type Interventional
Contact Name
Contact Phone 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials)
Condition Lymphoma, B-Cell
Detail for Health Professional (on clinicaltrials.gov)
More clinical trials by this PI